Abstract 2388
Background
EV-201 (NCT03219333) is a single-arm, 2-cohort study of EV in mUC patients treated with prior CPI and platinum-containing chemotherapy (Cohort 1) or a CPI and no prior chemotherapy and are cisplatin-ineligible (Cohort 2). The confirmed ORR rate was 44%. Patient-reported outcome (PRO) measures were included in EV-201 as exploratory endpoints. Our objective was to explore the impact of EV on QoL in Cohort 1 of EV-201.
Methods
Two validated instruments were included (EORTC QLQ-C30 v3 and EQ-5D-3L). The 30-item EORTC QLQ-C30 measures functioning, symptoms, and financial impact with scores ranging from 0 to 100. The 5-item EQ-5D measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted to a score ranging from 0 to 1, with 0 representing death and 1 representing perfect health. The EQ-5D also records self-rated health status on a 0-100 visual analogue scale (VAS). Assessments were completed at baseline and start of each cycle.
Results
Of 125 subjects from Cohort 1, 120 (96%) received EV and completed both instruments at baseline. Across all cycles, >86% of subjects with available data at each cycle completed both instruments. QLQ-C30 domain scores, inclusive of general QoL, functioning, and symptom scores, remained stable over time. Some domains demonstrated trends toward improvement across the study period (e.g. emotional, role, and social functioning, as well as pain, fatigue, appetite loss, constipation, and diarrhea) (Table). EQ-5D utility and VAS scores also remained stable throughout the treatment period. Variability and small sample size limit definitive conclusions.Table:
921P Patient reported outcomes at baseline, cycle 5, and cycle 10
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Mean (SD) Scores | Baseline n = 120 | Cycle 5 n = 59 | Cycle 10 n = 12 |
---|---|---|---|
Global quality of life | 63.0 (20.8) | 65.4 (19.8) | 69.4 (25.0) |
Functional domains | |||
Physical functioning | 76.4 (20.8) | 78.9 (16.7) | 92.2 (8.4) |
Role functioning | 73.3 (27.8) | 74.3 (23.2) | 84.7 (11.1) |
Emotional functioning | 81.7 (18.4) | 85.3 (17.7) | 86.8 (11.5) |
Cognitive functioning | 85.3 (19.2) | 83.9 (18.8) | 93.1 (13.2) |
Social functioning | 73.5 (26.1) | 76.3 (25.7) | 86.1 (21.1) |
Symptom scales | |||
Fatigue | 35.3 (22.9) | 36.4† (21.1) | 17.6† (12.9) |
Nausea and vomiting | 9.0 (15.9) | 5.5† (13.0) | 1.4† (4.8) |
Dyspnoea | 16.9 (23.4) | 17.5† (27.5) | 13.9† (17.2) |
Insomnia | 27.2 (28.7) | 22.4† (22.8) | 11.1† (16.4) |
Appetite loss | 24.7 (30.1) | 23.6† (25.8) | 11.1† (25.9) |
Constipation | 24.4 (30.5) | 13.2† (20.7) | 8.3† (15.1) |
Diarrhea | 8.9 (18.2) | 6.8† (16.1) | 5.6† (13.0) |
Pain | 29.9 (28.7) | 22.3† (26.6) | 4.2† (7.5) |
Financial difficulties | 18.2 (30.0) | 19.2† (27.8) | 27.8† (27.8) |
EuroQol 5 dimension 3 level Questionnaire (EQ-5D-3L) Mean (SD) scores | |||
Visual analogue scale (VAS) | 66.9 (20.5) | 67.1 (20.8) | 78.4 (27.3) |
Utility score | 0.795 (0.163) | 0.809 (0.148) | 0.910 (0.102) |
Higher scores represent a positive effect except for symptom domains as marked with †, where higher scores represent greater symptom burden. SD – standard deviation.
Conclusions
Findings demonstrate that QoL is either maintained or improved for patients on treatment with EV, which complement the efficacy and safety results from EV-201 Cohort 1.
Clinical trial identification
NCT03219333.
Editorial acknowledgement
Lisa Bloudek of Curta, funded by Seattle Genetics. Shang-Ying Liang of Seattle Genetics provided statistical support and QC of results.
Legal entity responsible for the study
Seattle Genetics Inc.
Funding
Seattle Genetics, Inc. and Astellas Pharma, Inc.
Disclosure
B.A. McGregor: Advisory / Consultancy: Astellas Pharma Inc.; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Decibel Therapeutics; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Exelixis; Advisory / Consultancy: Genentech; Advisory / Consultancy: Janssen; Advisory / Consultancy: Nextar; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy: AstraZeneca; Research grant / Funding (self), Research grant / Funding (institution): Calithera Biosciences. P.H. O’Donnell: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Shareholder / Stockholder / Stock options: Allergan; Shareholder / Stockholder / Stock options: PrescriptIQ; Honoraria (self), Honoraria (institution): Astellas Pharma Inc.; Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution): Genentech; Honoraria (self), Honoraria (institution): Harrison Consulting Group; Honoraria (self), Honoraria (institution): Inovio; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution), Non-remunerated activity/ies, Other Relationship: Janssen; Honoraria (self), Honoraria (institution): Kantar Health; Research grant / Funding (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Honoraria (institution): OncLive; Honoraria (self), Honoraria (institution): Parexel; Honoraria (self), Honoraria (institution): Quintiles; Research grant / Funding (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (self), Research grant / Funding (institution): Acerta; Non-remunerated activity/ies, Other Relationship: Advance Medical; Licensing / Royalties: Named as co-inventor on pending patent for a genomic prescribing system for medication prescribing. A. Balar: Advisory / Consultancy: Astellas Pharma Inc.; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Cerulean Pharma; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Genentech; Advisory / Consultancy: Incyte; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck; Advisory / Consultancy: Pfizer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics. D.P. Petrylak: Advisory / Consultancy: Astellas Pharma Inc.; Research grant / Funding (self), Research grant / Funding (institution): Astellas Medivation; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Bayer; Advisory / Consultancy: Bellicum Pharma; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Dendreon; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Ferring; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Johnson&Johnson; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Millennium; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): MedImmune; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Tyme; Research grant / Funding (self), Research grant / Funding (institution): Agensys; Research grant / Funding (self), Research grant / Funding (institution): Clovis Onc; Research grant / Funding (self), Research grant / Funding (institution): Endocyte; Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Lilly; Advisory / Consultancy: Medivation; Research grant / Funding (self), Research grant / Funding (institution): Genentech; Research grant / Funding (self), Research grant / Funding (institution): Innocrin Pharma; Research grant / Funding (self), Research grant / Funding (institution): Merck; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Progenics; Research grant / Funding (self), Research grant / Funding (institution): Sotio. J.E. Rosenberg: Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Agensys; Honoraria (self), Honoraria (institution): AstraZeneca; Advisory / Consultancy: AstraZeneca/MedImmune; Advisory / Consultancy: Bayer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Inovo Pharmaceuticals; Advisory / Consultancy: Lilly; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Merck; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Seattle Genetics; Shareholder / Stockholder / Stock options: Illumina; Honoraria (self), Honoraria (institution): Medcape; Honoraria (self), Honoraria (institution): Peerview; Honoraria (self), Honoraria (institution): UpToDate; Honoraria (self), Honoraria (institution): Vindico; Licensing / Royalties: Predictor of Platinum sensitivity; Research grant / Funding (self), Research grant / Funding (institution): Incyte; Research grant / Funding (self), Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Oncogenex; Research grant / Funding (self), Research grant / Funding (institution): Viralytics. E. Yu: Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Churchill Pharma; Advisory / Consultancy, Research grant / Funding (institution): Dendreon; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: QED Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy: Tolmar; Advisory / Consultancy: Pharmacyclics; Research grant / Funding (institution): Agensys; Research grant / Funding (self): Daiichi Sankyo. D.I. Quinn: Full / Part-time employment: University of Southern California; Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Dendreon; Advisory / Consultancy: Exelixis; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Sanofi. S.N. Shah: Full / Part-time employment: Astellas Pharma Inc. J. Pinelli: Shareholder / Stockholder / Stock options, Full / Part-time employment: Seattle Genetics. Z. Hepp: Shareholder / Stockholder / Stock options, Full / Part-time employment: Seattle Genetics. M. Galsky: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Genentech; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Dracen; Advisory / Consultancy: Dragonfly Therapeutics; Advisory / Consultancy: Astellas; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Janssen; Research grant / Funding (institution): Dendreon; Research grant / Funding (institution): Roche/Genentech.
Resources from the same session
5383 - A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Presenter: Mary Grace Kelly
Session: Poster Display session 3
Resources:
Abstract
5084 - The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Presenter: Rachel Taylor
Session: Poster Display session 3
Resources:
Abstract
4328 - Life beyond cancer: Occupational health care service support in returning work experienced by cancer survivals
Presenter: Minna Nurmi
Session: Poster Display session 3
Resources:
Abstract
3337 - Investigating the factors related to primary caregivers' burden in oncology patients in Greece
Presenter: Ourania Govina
Session: Poster Display session 3
Resources:
Abstract
3387 - Factors Influencing the Level of Emotional Support from Nurses Perceived by Patients Undergoing Haematopoietic Stem Cell Transplantation in Protective Isolation
Presenter: Michela Piredda
Session: Poster Display session 3
Resources:
Abstract
935 - Progressive Muscle Relaxation and Guided Imagery Techniques and the Way of Coping of Parents of Children with Malignancies: A randomized controlled trial
Presenter: Tsitsi Theologia
Session: Poster Display session 3
Resources:
Abstract
3457 - Pharmacist and Nurse Led Melanoma Immunotherapy Clinic
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
5160 - Measuring the impact of the Irish Cancer Society's Cancer Information Services
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
4297 - It's Great to Talk
Presenter: Noreen Andersen
Session: Poster Display session 3
Resources:
Abstract
4444 - Impact of Burn-Out Syndrome in Oncology personnel and its improvement through specific interventions
Presenter: Inmaculada Ortega
Session: Poster Display session 3
Resources:
Abstract